We serve Chemical Name:2-(1H-indol-2-yl)propanenitrile CAS:76017-87-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(1H-indol-2-yl)propanenitrile
CAS.NO:76017-87-3
Synonyms:2-(1-CYANOETHYL)INDOLE;|A-Methyl-1H-indole-2-acetonitrile;2,6-DICB UNLABELED;1H-Indole-2-acetonitrile,a-methyl
Molecular Formula:C11H10N2
Molecular Weight:170.21000
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:39.58000
Exact Mass:170.08400
LogP:2.79498
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-(1-CYANOETHYL)INDOLE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1H-Indole-2-acetonitrile,a-methyl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1H-Indole-2-acetonitrile,a-methyl Use and application,|A-Methyl-1H-indole-2-acetonitrile technical grade,usp/ep/jp grade.
Related News: Onyx Scientific, a small molecule API contract development and manufacturing organization (CDMO) has received a commercial API license for its UK facility. N-[4-[(1-methylbenzimidazol-2-yl)sulfamoyl]phenyl]acetamide manufacturers So-called “off” periods occur when a Parkinson’s patient has difficulty moving about and occur when the effect of the last dose of another common Parkinson’s drug, known as levodopa, wears off. Naphthalene-1-sulfonic acid (4-hydroxymethyl-cyclohexylmethyl)-amide suppliers Meanwhile, EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization for Moderna’s Covid-19 vaccine, now known as Spikevax, to include adolescents 12 years of age and older. 3-hydroxymethyl-2,3′-bipyridyl vendor & factory By integrating biocatalysis into ongoing and newly launched projects, Wavelength Pharmaceuticals has shown that it is possible to reduce overall costs by as much as 30%.,So-called “off” periods occur when a Parkinson’s patient has difficulty moving about and occur when the effect of the last dose of another common Parkinson’s drug, known as levodopa, wears off.
